|1y Target Est:||N/A|
|Next Earnings Date:||N/A|
|Day's Range:||N/A - N/A|
|Avg Vol (3m):||N/A|
|Div & Yield:||N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in .
- Ex-SAC manager Martoma fails to end part of insider caseReuters(Tue, Dec 17)
- U.S. judge rejects bid by ex-SAC manager to dismiss part of insider caseReuters(Tue, Dec 17)
- US judge rejects bid by ex-SAC manager to dismiss part of insider caseReuters(Tue, Dec 17)
- Roche in deal worth up to $600 mln for Prothena Parkinson's drugReuters(Thu, Dec 12)
- Ex-SAC trader points to Cohen testimony in insider trading caseReuters(Sat, Dec 7)
- Elan wins shareholder approval to complete Perrigo saleReuters(Mon, Nov 18)
- The prosecutors with SAC Capital in their crosshairsReuters(Sun, Nov 17)
- Biogen's new MS drug tops expectations; ups 2013 forecastReuters(Mon, Oct 28)
- Insider trading trial of SAC's Martoma delayed to JanuaryReuters(Tue, Sep 24)
- Insider trading trial of SAC's Martoma delayed until JanuaryReuters(Tue, Sep 24)
- Money manager Vilar's conviction upheld, new sentence orderedat Reuters(Fri, Aug 30)
- Drugmaker Elan plans to explore sale of companyAP(Fri, Jun 14)
- No Reports available for DRX.IR at this time.
|Forward P/E (1 yr):||N/A|
|Annual EPS Est
|Quarterly EPS Est
|PEG Ratio (5 yr expected):||N/A|
No business summary available for DRX.IR.